Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

OSTEOPROMOTION BY A CALCIUM PHOSPHATE CEMENT AND AN OSTEOGENETIC TRANSGLUTAMINASE (FXIII)



Abstract

Purpose: Current research is focusing on the imitation of the optimal osteoconductive and osteoinductive properties of bone graft. We used in this study a β-trical-cium-phosphate scaffold impregnated with an osteogenetic transglutaminase (plasmatransglutaminase, FXIII, (Fibrogammin®)).

Methods: Release study: 27 & #946;-TCP discs (8x10mm) were impregnated with 10, 40 and 100 IU of FXIII. The release was measured with ELISA.|Animal study: A bilateral tibial metaphyseal defect (8.5 x 20 mm) was performed in eighteen adult sheep. The defects were filled with a & #946;-TCP cylinder (chronOS®, Synthes) in 16 sheep and left unfilled in 2 sheep (control group). The cylinders were impregnated with autologous venous blood, autologous bone marrow aspirate from the sternum and 125 IU FXIII in 4 sheep each or left unfilled and a daily dose of 1250 IU FXIII administered iv. over 14 days. After 6 and 12 weeks QCT, histology and histological analysis was performed.

Results: Release study: We found a linear release of FXIII with a plateau after 48 h. Until then on average 18% of the total dose was release from the scaffold. Animal study: The QCT analysis found unspecific changes in all group without any clear results regarding remodeling of the scaffold. The histological analysis showed the best bone ingrowth after 6 weeks in the bone marrow group and after 12 weeks in the local F XIII with on average 10% more bone ingrowth than in any other group. The best remodeling of the inner area in the scaffold was also seen in the local F XIII group.

Conclusions: FXIII is only partially released from a β-TCP scaffold. At least 80% of the dose remains in the scaffold after 48h. F XIII has a good osteogenetic property which is at least as good as bone marrow and better than venous blood; however a local application of F XIII is preferable to iv. administration. It stimulates osteoblast migration and proliferation in a β-TCP scaffold and causes a remodelling on the inside of the scaffold.

Funding : Commerical funding

Funding Parties : Grant by the AO Research Institute Davos, Switzerland and Synthes, Oberador, Switzerland

Correspondence should be addressed to Cynthia Vezina, Communications Manager, COA, 4150-360 Ste. Catherine St. West, Westmount, QC H3Z 2Y5, Canada